Prostate Cancer, Version 4.2023

被引：279

作者：

Schaeffer, Edward M. ^{[1
]}

Srinivas, Sandy ^{[2
]}

Adra, Nabil ^{[3
]}

An, Yi ^{[4
]}

Barocas, Daniel ^{[5
]}

Bitting, Rhonda ^{[6
]}

Bryce, Alan ^{[7
]}

Chapin, Brian ^{[8
]}

Cheng, Heather H. ^{[9
]}

D'Amico, Anthony Victor ^{[10
]}

Desai, Neil ^{[11
]}

Dorff, Tanya ^{[12
]}

Eastham, James A. ^{[13
]}

Farrington, Thomas A. ^{[14
]}

Gao, Xin ^{[10
]}

Gupta, Shilpa ^{[15
,16
]}

Guzzo, Thomas ^{[17
]}

Ippolito, Joseph E. ^{[18
,19
]}

Kuettel, Michael R. ^{[20
]}

Lang, Joshua M. ^{[21
]}

Lotan, Tamara ^{[22
]}

Mckay, Rana R. ^{[23
]}

Morgan, Todd ^{[24
]}

Netto, George ^{[25
]}

Pow-Sang, Julio M. ^{[26
]}

Reiter, Robert ^{[27
]}

Roach, Mack ^{[28
]}

Robin, Tyler ^{[29
]}

Rosenfeld, Stan ^{[30
]}

Shabsigh, Ahmad ^{[31
,32
]}

Spratt, Daniel ^{[15
,16
]}

Teply, Benjamin A. ^{[33
]}

Tward, Jonathan ^{[34
]}

Valicenti, Richard ^{[35
]}

Wong, Jessica Karen ^{[36
]}

Shead, Dorothy A. ^{[37
]}

Snedeker, Jenna ^{[37
]}

Freedman-Cass, Deborah A. ^{[37
]}

机构：

[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[2] Stanford Canc Inst, Stanford, CA USA

[3] Indiana Univ, Melvin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN USA

[4] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[5] Vanderbilt Ingram Canc Ctr, Vanderbilt, TN USA

[6] Duke Canc Inst, Durham, NC USA

[7] Mayo Clin, Comprehens Canc Ctr, Jacksonville, FL USA

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[9] Fred Hutchinson Canc Ctr, Sunnyside, WA USA

[10] Dana Farber Brigham & Womens Canc Ctr, Mass Gen Canc Ctr, Boston, MA USA

[11] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[12] City Hope Natl Canc Ctr, Monrovia, CA USA

[13] Mem Sloan Kettering Canc Ctr, Commack, NY USA

[14] Prostate Hlth Educ Network PHEN, Quincy, MA USA

[15] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[16] Cleveland Clin Taussig Canc Inst, Cleveland, OH USA

[17] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[18] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[19] Washington Univ, Sch Med, St Louis, MO USA

[20] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[21] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[22] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Mcadoo, PA USA

[23] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA

[24] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA

[25] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[26] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[27] UCLA, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[28] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[29] Univ Colorado, Canc Ctr, Denver, CO USA

[30] Univ Calif San Francisco, Patient Serv Comm Chair, San Francisco, CA USA

[31] Ohio State Univ, James Canc Hosp, Comprehens Canc Ctr, Columbus, OH USA

[32] Solove Res Inst, Columbus, OH USA

[33] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[34] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[35] UC Davis Comprehens Canc Ctr, Sacramento, CA USA

[36] Fox Chase Canc Ctr, Philadelphia, PA USA

[37] Natl Comprehens Canc Network, Rockledge, FL USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2023年 / 21卷 / 10期

关键词：

RANDOMIZED PHASE-III; MITOXANTRONE PLUS PREDNISONE; ANDROGEN-DEPRIVATION THERAPY; PLATINUM-BASED CHEMOTHERAPY; POST-HOC ANALYSIS; QUALITY-OF-LIFE; METASTASIS-FREE SURVIVAL; GETUG-AFU; 15; ABIRATERONE ACETATE; OPEN-LABEL;

D O I：

10.6004/jnccn.2023.0050

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment inten-sification is strongly recommended for patients with metastatic castra-tion-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision -making approach in all disease settings based on patient preferen-ces, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.

引用

页码：1067 / 1096

页数：30

共 165 条

[41] Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1) an-label, 2 trial [J].

de Bono, Johann S. ;

Mehra, Niven ;

Scagliotti, Giorgio, V ;

Castro, Elena ;

Dorff, Tanya ;

Stirling, Adam ;

Stenzl, Arnulf ;

Fleming, Mark T. ;

Higano, Celestia S. ;

Saad, Fred ;

Buttigliero, Consuelo ;

van Oort, Inge M. ;

Laird, A. Douglas ;

Mata, Marielena ;

Chen, Hsiang-Chun ;

Healy, Cynthia G. ;

Czibere, Akos ;

Fizazi, Karim .

LANCET ONCOLOGY, 2021, 22 (09) :1250-1264

[42] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[43] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

[44] Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered A Post Hoc Analysis of the Mainsail Study [J].

de Morree, Ellen S. ;

Vogelzang, Nicholas J. ;

Petrylak, Daniel P. ;

Budnik, Nikolay ;

Wiechno, Pawel J. ;

Sternberg, Cora N. ;

Doner, Kevin ;

Bellmunt, Joaquim ;

Burke, John M. ;

de Olza, Maria Ochoa ;

Choudhury, Ananya ;

Gschwend, Juergen E. ;

Kopyltsov, Evgeny ;

Flechon, Aude ;

van As, Nicolas ;

Houede, Nadine ;

Barton, Debora ;

Fandi, Abderrahim ;

Jungnelius, Ulf ;

Li, Shaoyi ;

Li, Jack Shiansong ;

Li, Shiansong ;

de Wit, Ronald .

JAMA ONCOLOGY, 2017, 3 (01) :68-75

[45] Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer [J].

de Wit, Ronald ;

de Bono, Johann ;

Sternberg, Cora N. ;

Fizazi, Karim ;

Tombal, Bertrand ;

Wuelfing, Christian ;

Kramer, Gero ;

Eymard, Jean-Christophe ;

Bamias, Aristotelis ;

Carles, Joan ;

Iacovelli, Roberto ;

Melichar, Bohuslav ;

Sverrisdottir, Asgerdur ;

Theodore, Christine ;

Feyerabend, Susan ;

Helissey, Carole ;

Ozatilgan, Ayse ;

Geffriaud-Ricouard, Christine ;

Castellano, Daniel ;

de Wit, Ronald ;

de Bono, Johann ;

Sternberg, Cora N. ;

Fizazi, Karim ;

Tombal, Bertrand ;

Wulfing, Christian ;

Kramer, Gero ;

Eymard, Jean-Christophe ;

Bamias, Aristotelis ;

Carles, Joan ;

Iacovelli, Roberto ;

Melichar, Bohuslav ;

Sverrisdottir, Asgerour ;

Theodore, Christine ;

Feyerabend, Susan ;

Helissey, Carole ;

Ozatilgan, Ayse ;

Geffriaud-Ricouard, Christine ;

Castellano, Daniel .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (26) :2506-2518

[46] TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer [J].

Denmeade, Samuel R. ;

Wang, Hao ;

Agarwal, Neeraj ;

Smith, David C. ;

Schweizer, Michael T. ;

Stein, Mark N. ;

Assikis, Vasileios ;

Twardowski, Przemyslaw W. ;

Flaig, Thomas W. ;

Szmulewitz, Russell Z. ;

Holzbeierlein, Jeffrey M. ;

Hauke, Ralph J. ;

Sonpavde, Guru ;

Garcia, Jorge A. ;

Hussain, Arif ;

Sartor, Oliver ;

Mao, Shifeng ;

Cao, Harry ;

Fu, Wei ;

Wang, Ting ;

Abdallah, Rehab ;

Lim, Su Jin ;

Bolejack, Vanessa ;

Paller, Channing J. ;

Carducci, Michael A. ;

Markowski, Mark C. ;

Eisenberger, Mario A. ;

Antonarakis, Emmanuel S. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (12) :1371-+

[47] National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening [J].

Drazer, Michael W. ;

Huo, Dezheng ;

Eggener, Scott E. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (22) :2416-U18

[48] RESPONSE TO FLUTAMIDE WITHDRAWAL IN ADVANCED PROSTATE-CANCER IN PROGRESSION UNDER COMBINATION THERAPY [J].

DUPONT, A ;

GOMEZ, JL ;

CUSAN, L ;

KOUTSILIERIS, M ;

LABRIE, F .

JOURNAL OF UROLOGY, 1993, 150 (03) :908-913

[49] Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA [J].

Eisenberger, Mario ;

Hardy-Bessard, Anne-Claire ;

Kim, Choung Soo ;

Geczi, Lajos ;

Ford, Daniel ;

Mourey, Loic ;

Carles, Joan ;

Parente, Phillip ;

Font, Albert ;

Kacso, Gabriel ;

Chadjaa, Mustapha ;

Zhang, Wenping ;

Bernard, John ;

de Bono, Johann .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) :3198-+

[50] Recent Trends in PSA Testing and Prostate Cancer Incidence A Look at Context [J].

Etzioni, Ruth ;

Gulati, Roman .

JAMA ONCOLOGY, 2016, 2 (07) :955-956

← 1 2 3 4 5 6 7 8 9 10 →